Difference between revisions of "Tbo-filgrastim (Granix)"
Jump to navigation
Jump to search
(updated content) |
m |
||
| Line 14: | Line 14: | ||
==Also known as== | ==Also known as== | ||
| − | Neutroval | + | *'''Brand names:''' Granix, Neutroval |
==References== | ==References== | ||
| Line 20: | Line 20: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | [[Category: | + | [[Category:Subcutaneous medications]] |
| − | [[Category:Granulocyte | + | [[Category:Granulocyte colony-stimulating factors]] |
[[Category:Drugs FDA approved in 2012]] | [[Category:Drugs FDA approved in 2012]] | ||
Revision as of 03:39, 17 November 2017
General information
Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation‚ differentiation, and some end-cell functional activation.[1][2][3]
Route: SC
Extravasation: no known issues
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Tbo-filgrastim (Granix) package insert[1]
- Tbo-filgrastim (Granix) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/29/2012: Initial FDA approval "for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia."
Also known as
- Brand names: Granix, Neutroval